Breast Cancer
Conditions
Keywords
breast cancer, PET/CT, HER2 expression, ADC therapy
Brief summary
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with ADC therapy
Interventions
RADIATIONHER2 expression of PET imaging
Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in breast patients treated with ADC therapy
Sponsors
Peking University Cancer Hospital & Institute
The Affiliated Hospital of Qingdao University
North Sichuan Medical College
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Aged ≥18 years old; ECOG 0 or 1; 2. Patients with HER2 positive or low tumors; 3. Receives neoadjuvant therapy 4. Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions; 5. Life expectancy \> 3 months -
Exclusion criteria
1. Significant hepatic or renal dysfunction; 2. Is pregnant or ready to pregnant; 3. Cannot keep their states for half an hour; 4. Refused to join the clinical research; 5. Suffering from claustrophobia or other mental disorders; 6. Any other situation that researchers considered it unsuitable to participate in the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in SUVmax before and after treatment | Before treatment, 9 weeks after treatment, before surgery | The uptake of the tracer in the primary and metastatic tumor lesions by measuring standardized uptake value (SUV) on PET/CT |
Countries
China
Contacts
CONTACTXiaoyi Guo, PhD
CONTACTYannan Yuan
Outcome results
None listed